… erlotinib/gefitinib arm in the current analysis but did not change from baseline in the osimertinib
arm, which may reflect differences in CNS progression between the two treatment arms. …

… investigate the outcomes of gefitinib and erlotinib in patients with non-small cell lung
cancer … of this study design, it is not possible to directly compare the outcomes of the first-generation …

… 17.3 months for gefitinib, 12.4 months for erlotinib, and 23.3 … % CI, 0.47–0.83) compared
with gefitinib or erlotinib. In the … CNS failure compared with gefitinib or erlotinib after adjusting …

… of TKI treatment between afatinib and osimertinib [16, 17]. However, the median follow-up
time was not … Thus, we conducted the present study in order to compare the clinical outcomes …

… Our results show better 1-year OS rate with afatinib than gefitinib but not erlotinib. We did …
Regarding this finding we did not performed comparative analysis between our results and …

… ) are recommended as first-line treatment in non-small cell lung cancer (NSCLC) patients with
… comparisons between regimens with first-line use of afatinib, gefitinib or erlotinib, followed …

… to be treated as a chronic disease [10]. In this systematic review, we will compare the use of
gefitinib as an alternative treatment in NSCLC and compare it to traditional chemotherapies. …

… )s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) …
have on the clinical outcome of sequential osimertinib treatment. Compared with other real-…

… In conclusion, the OS benefit from first-line treatment with dacomitinib versus gefitinib
was maintained after extended follow-up in patients with advanced NSCLC with EGFR-activating …

… clinical outcomes, we demonstrated that anlotinib might be a favorable regimen for use
after … However, our results showed that there was no difference in sex and smoking status. …